Melanoma

Philip Friedlander, Corazon B. Cajulis

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

Melanoma accounts for most skin cancer-related mortality. Limiting exposure to ultraviolet radiation can decrease the risk of developing melanoma. The stage at presentation provides important prognostic information and guides treatment planning. Stage I and II melanomas are localized to the primary site and managed surgically with wide excision and sentinel lymph node (SLN) biopsy if the melanoma is >1 mm thick and selectively if 0.76-1 mm thick. Management of stage III melanoma includes wide excision and SLN biopsy with consideration of lymphadenectomy if the SLN is involved. Adjuvant therapy is considered in melanomas >4 mm thick or stage III. Stage IV melanoma is usually treated with systemic therapy. Treatment options depend on the presence of mutation at V600 BRAF which activates the mitogen activated protein kinase signaling pathway. Recent FDA approval of immune checkpoint inhibitors and MAPK pathway inhibitors represent significant advances in the management of melanoma.

Original languageEnglish
Title of host publicationOncology
Publisherwiley
Pages204-213
Number of pages10
ISBN (Electronic)9781119189596
ISBN (Print)9781119189558
DOIs
StatePublished - 30 Aug 2019

Keywords

  • Diagnostic algorithms
  • Evidence-based clinical data
  • Immunotherapy
  • Melanoma
  • Mitogen activated protein kinase targeted therapy
  • Sentinel lymph node biopsy
  • Sun avoidance measures
  • Treatment algorithms

Fingerprint

Dive into the research topics of 'Melanoma'. Together they form a unique fingerprint.

Cite this